PRESS-RELEASE ·Filed Mar 24, 2026
Press release: earnings
Actionable Insight • Neutral
Traders should monitor the upcoming earnings call on March 30 for actual financial results and clinical development updates, which could move the stock given the company's small market cap.
Final — all horizons settled through T+60d
PDSB ▲ +49.32% at T+60d
NEUTRAL call ✓ call won +49.32% · α vs SPY +35.87% · entry $0.6350 → $0.9482
T+1d
+0.79%
call +0.79% · α +2.56%
$0.6400
settled 6mo ago
T+5d
-4.57%
call -4.57% · α -4.32%
$0.6060
settled 6mo ago
T+20d
+46.14%
call +46.14% · α +38.28%
$0.9280
settled 5mo ago
T+60d
+49.32%
call +49.32% · α +35.87%
$0.9482
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
PDS Biotechnology announced it will report its Q4 and full-year 2025 financial results and provide a clinical update on March 30, 2026. The press release contains no actual financial or operational data, only a notification of an upcoming earnings call.
Key Facts
- PDS Biotech will report financial results for Q4 and full-year 2025 on March 30, 2026.
- The announcement includes a clinical programs and corporate update.
- No financial figures, guidance, or operational results were disclosed in this release.
Financial Impact
No financial data disclosed
Risk Factors
- Lack of disclosed data limits immediate trading utility.
- Biotech stocks with no revenue are highly sensitive to clinical trial updates, which may be positive or negative.
Market Snapshot
Exchange
Nasdaq
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261723 |
17 reports for PDSB
70% Hit rate best @ T+20▲ +71.95%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7485 (−149.50%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7485 (+258.31%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7485 (−220.97%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7485 (−191.25%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7485 (−4.61%) |
Jun 26, 2026 14w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7485 (−16.75%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7485 (+22.03%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7485 (−26.62%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7485 (−35.47%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7485 (−43.72%) |
Showing 10 of 17
US Market Status
Market Closed — Opens Mon (64h 40m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access